These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30610953)

  • 1. Investigations of the mechanism behind the rapid absorption of nano-amorphous abiraterone acetate.
    Basa-Dénes O; Solymosi T; Ötvös Z; Angi R; Ujhelyi A; Jordán T; Heltovics G; Glavinas H
    Eur J Pharm Sci; 2019 Mar; 129():79-86. PubMed ID: 30610953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements.
    Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Semsey S; Molnár L; Ránky S; Filipcsei G; Heltovics G; Glavinas H
    Int J Pharm; 2017 Oct; 532(1):427-434. PubMed ID: 28919099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect.
    Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Molnár L; McDermott J; Zann V; Church A; Mair S; Filipcsei G; Heltovics G; Glavinas H
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):723-728. PubMed ID: 28776077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability Enhancement and Food Effect Elimination of Abiraterone Acetate by Encapsulation in Surfactant-Enriched Oil Marbles.
    Boleslavská T; Rychecký O; Krov M; Žvátora P; Dammer O; Beránek J; Kozlík P; Křížek T; Hořínková J; Ryšánek P; Roušarová J; Canová NK; Šíma M; Slanař O; Štěpánek F
    AAPS J; 2020 Sep; 22(6):122. PubMed ID: 32978690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man.
    Geboers S; Stappaerts J; Mols R; Snoeys J; Tack J; Annaert P; Augustijns P
    J Pharm Sci; 2016 Sep; 105(9):2974-2981. PubMed ID: 27061460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate.
    Schultz HB; Meola TR; Thomas N; Prestidge CA
    Int J Pharm; 2020 Mar; 577():119069. PubMed ID: 31981706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans.
    Sakai Y; Fukami T; Nagaoka M; Hirosawa K; Ichida H; Sato R; Suzuki K; Nakano M; Nakajima M
    Life Sci; 2021 Nov; 284():119896. PubMed ID: 34450168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: in vitro, rat in situ and human in vivo studies.
    Stappaerts J; Geboers S; Snoeys J; Brouwers J; Tack J; Annaert P; Augustijns P
    Eur J Pharm Biopharm; 2015 Feb; 90():1-7. PubMed ID: 25592324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.
    Nirogi R; Ravula J; Benade V; Goyal VK; Pandey SK; Dogiparti D; Jayarajan P; Kalaikadhiban I; Jetta S; Palacharla VRC
    Cancer Chemother Pharmacol; 2024 Mar; 93(3):253-264. PubMed ID: 38157042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of new formulation concepts for abiraterone acetate bioavailability enhancement based on the inhibition of pH-induced precipitation.
    Boleslavská T; Světlík S; Žvátora P; Bosák J; Dammer O; Beránek J; Kozlík P; Křížek T; Kutinová Canová N; Šíma M; Slanař O; Štěpánek F
    Eur J Pharm Biopharm; 2020 Jun; 151():81-90. PubMed ID: 32298757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supersaturated-Silica Lipid Hybrids Improve in Vitro Solubilization of Abiraterone Acetate.
    Schultz HB; Joyce P; Thomas N; Prestidge CA
    Pharm Res; 2020 Mar; 37(4):77. PubMed ID: 32236761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics.
    Lubberman FJE; Benoist GE; Gerritsen W; Burger DM; Mehra N; Hamberg P; van Oort I; van Erp NP
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1179-1185. PubMed ID: 31515667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.
    Chi KN; Spratlin J; Kollmannsberger C; North S; Pankras C; Gonzalez M; Bernard A; Stieltjes H; Peng L; Jiao J; Acharya M; Kheoh T; Griffin TW; Yu MK; Chien C; Tran NP
    J Clin Pharmacol; 2015 Dec; 55(12):1406-14. PubMed ID: 26096139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the dissolution behaviors and bioavailability of abiraterone acetate via multicomponent crystal forms.
    Yang Z; Yang Y; Xia M; Dai W; Zhu B; Mei X
    Int J Pharm; 2022 Feb; 614():121460. PubMed ID: 35026315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies.
    Goldwater R; Hussaini A; Bosch B; Nemeth P
    Clin Pharmacokinet; 2017 Jul; 56(7):803-813. PubMed ID: 28425029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmented experimental design for bioavailability enhancement: a robust formulation of abiraterone acetate.
    Katekar R; Sen S; Riyazuddin M; Husain A; Garg R; Verma S; Mitra K; Gayen JR
    J Liposome Res; 2023 Mar; 33(1):65-76. PubMed ID: 35521749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the Mechanisms behind the Positive Food Effect of Abiraterone Acetate: In Vitro and Rat In Situ Studies.
    Braeckmans M; Augustijns P; Mols R; Servais C; Brouwers J
    Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids.
    Schultz HB; Wignall AD; Thomas N; Prestidge CA
    Int J Pharm; 2020 May; 582():119264. PubMed ID: 32278053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development, Characterization, and Optimization of a Novel Abiraterone Acetate Formulation to Improve Biopharmaceutical Attributes Aided by Pharmacokinetic Modelling.
    Dahiya S; Savjani K; Savjani J
    AAPS PharmSciTech; 2021 Nov; 23(1):4. PubMed ID: 34811624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Abiraterone Acetate Nanocrystal Tablets to Enhance Oral Bioavailability: Formulation Optimization, Characterization, In Vitro Dissolution and Pharmacokinetic Evaluation.
    Liu Y; Li Y; Xu P; Shen Y; Tang B; Wang Q
    Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.